Patients Using Selective Serotonin Reuptake Inhibitors Have High Prevalence Of Acute Periapical Abscesses
- byDoctor News Daily Team
- 21 July, 2025
- 0 Comments
- 0 Mins
Patients using selective serotonin reuptake inhibitors have a high prevalence of acute periapical abscesses suggests a new study published in the Special Care in Dentistry.
Depression and anxiety are major health problems impacting the quality of life of the affected individuals and can lead to significant disability. According to the World Health Organization (WHO), these psychological conditions are the second-highest cause of disability worldwide. Depression and anxiety are severe health problems affecting millions of individuals worldwide. Consequently, the use of antidepressants has constantly been on the rise. Selective serotonin reuptake inhibitors (SSRIs) antidepressant are now commonly used due to fewer side effects as compared to other types of antidepressants. This study aimed to assess the prevalence of periapical abscesses (PAs)in patients using SSRIs. Integrated data of hospital patients was used. Data from the corresponding diagnosis codes for SSRIs and acute PAs was retrieved by searching the appropriate query in the database. The different diagnoses were coded using the international coding system ICD 10.
Diagnosis was made by calibrated dentists in a hospital setting based on clinical examination and imaging data. The odds ratio (OR) for the prevalence of acute PAs and its association with the use of SSRIs were calculated and analyzed statistically. It was found that the prevalence of acute PAs was significantly higher in patients using SSRIs as compared to the other hospital patient population. The OR was 2.8 and the difference between patients using SSRIs and patients who do not was statistically significant (p < .0001). Under the conditions of this study, it appears that the prevalence of acute PAs is higher in patients using SSRIs.
Reference:
Rotstein I, Katz J. Acute periapical abscesses in patients using selective serotonin reuptake inhibitors. Spec Care Dentist. 2024; 44: 143–147. https://doi.org/10.1111/scd.12789
Keywords:
Patients, selective serotonin, reuptake inhibitors, prevalence, acute periapical abscesses, Rotstein I, Katz J
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
Recent News
DME Gujarat extends PG Ayurveda, Homeopathy round...
- 05 November, 2025
NEET counselling: CENTAC publishes round 3 provisi...
- 05 November, 2025
Marksans Pharma UK arm gets marketing nod for Exem...
- 05 November, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.
0 Comments
Post a comment
No comments yet. Be the first to comment!